Welcome to our dedicated page for Syndax Pharmaceuticals SEC filings (Ticker: SNDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Syndax Pharmaceuticals filings document regulatory disclosures for a commercial-stage cancer-therapy company. Recent Form 8-K reports furnish quarterly and annual financial results, preliminary financial information, product-revenue updates for Revuforj and Niktimvo, business presentations and material product events, including the FDA approval of Revuforj for relapsed or refractory acute myeloid leukemia with a susceptible NPM1 mutation.
The company’s proxy materials cover board elections, executive compensation, equity-award valuation and shareholder voting matters. Other material-event filings address governance changes, including director departures, and Regulation FD disclosures tied to investor presentations and operating updates.
Syndax Pharmaceuticals reported first quarter 2026 revenue of $64.9 million, a 224% year-over-year increase driven by strong launches of Revuforj and Niktimvo. Revuforj net revenue reached $48.9 million, reflecting rapid uptake in relapsed or refractory NPM1-mutated and KMT2A-rearranged acute leukemias and growing use around stem cell transplant.
Niktimvo generated $55.1 million in net revenue at partner Incyte, producing $15.9 million of collaboration revenue for Syndax. Operating expenses declined modestly, and the net loss narrowed to $42.7 million, or $0.48 per share, compared with $84.8 million a year earlier.
The company ended the quarter with $352.1 million in cash, cash equivalents and short-term investments and 88.8 million common shares and prefunded warrants outstanding. Syndax guides to about $400 million in 2026 R&D plus SG&A (excluding $50 million non-cash stock compensation) and expects its current cash, investments, product and collaboration revenue, and interest income to support a path to profitability.
Syndax Pharmaceuticals Inc ownership disclosure: Vanguard Capital Management reports beneficial ownership of 4,457,143 shares of Common Stock, representing 5.05% of the class as of 03/31/2026. The filing states Vanguard has sole dispositive power over 4,457,143 shares and sole voting power over 634,564 shares. The report explains these holdings include securities held for Vanguard funds and managed accounts and names affiliate divisions exercising voting or dispositive power.
Syndax Pharmaceuticals Inc Schedule 13G/A shows The Vanguard Group reports 0 shares beneficially owned of Common Stock, representing 0% of the class. The filing explains an internal realignment effective January 12, 2026, under SEC Release No. 34-39538 causing certain Vanguard subsidiaries to report holdings separately.
Syndax Pharmaceuticals is a commercial-stage biopharma company focused on cancer and fibrotic diseases, now built around two FDA‑approved medicines and a broad development pipeline.
The company markets Revuforj (revumenib), a first‑in‑class oral menin inhibitor approved in the United States for relapsed or refractory acute leukemia with a KMT2A translocation and for relapsed or refractory acute myeloid leukemia with a susceptible NPM1 mutation in patients one year and older who lack satisfactory alternatives. Revuforj is being studied across the acute leukemia treatment continuum in multiple Phase 1–3 trials, including pivotal frontline combinations with venetoclax, azacitidine and intensive chemotherapy, and early programs in myelofibrosis and minimal residual disease.
Niktimvo (axatilimab‑csfr), a first‑in‑class CSF‑1R‑blocking antibody, is approved for chronic graft‑versus‑host disease after at least two prior systemic therapies in adults and pediatric patients weighing at least 40 kg. It showed a 75% overall response rate at the approved dose in the AGAVE‑201 study and is being co‑commercialized with Incyte in the United States, with Incyte holding ex‑U.S. rights. Axatilimab is in clinical development for newly diagnosed chronic GVHD and idiopathic pulmonary fibrosis.
The business is supported by multiple global license agreements for its core assets, extensive patent estates extending into the 2030s and 2040s, and a significant royalty financing with Royalty Pharma, which provided an upfront $350 million in exchange for a capped percentage of future U.S. axatilimab net sales.
Syndax Pharmaceuticals reported strong commercial growth for 2025 as it ramped launches of Revuforj and Niktimvo. Total revenue reached $68.7 million in the fourth quarter and $172.4 million for 2025, driven by Revuforj net revenue of $124.8 million and Niktimvo collaboration revenue of $42.4 million.
The company remains loss-making, with a 2025 net loss attributable to common stockholders of $285.4 million, or $3.29 per share, but narrowed its loss versus 2024. Cash, cash equivalents and short-term investments were $394.1 million as of December 31, 2025, supporting an R&D and SG&A expense outlook of about $400 million for 2026.
Management highlighted accelerating prescription trends, multiple late-stage trials for Revuforj across acute leukemia settings, and completion of enrollment in the Phase 2 IPF trial of axatilimab, with topline data expected in the fourth quarter of 2026 as it targets a path to profitability.
Syndax Pharmaceuticals Chief Executive Officer Michael A. Metzger reported a sale of common stock primarily to cover taxes. On 02/09/2026, he sold 17,159 shares of Syndax Pharmaceuticals common stock at a price of $21.028 per share.
The filing explains that this sale represents shares required to be sold to satisfy tax withholding obligations related to the vesting of restricted stock units, rather than a discretionary open-market sale of his full holdings. After this transaction, Metzger beneficially owned 491,690 shares of Syndax Pharmaceuticals common stock in direct ownership.
Syndax Pharmaceuticals Chief Financial Officer Keith A. Goldan reported a sale of common stock tied to tax withholding. On February 9, 2026, he sold 3,410 shares of Syndax common stock at $21.028 per share.
According to the filing, this sale represents shares required to be sold to cover tax withholding obligations arising from the vesting of restricted stock units, rather than a discretionary open-market sale. After this transaction, Goldan directly beneficially owns 140,429 shares of Syndax common stock.
Syndax Pharmaceuticals insider Michael A. Metzger filed a notice of proposed sale under Rule 144 to sell 17,159 common shares through Fidelity Brokerage Services LLC, with an aggregate market value of $360,826.32. The shares were acquired on 02/06/2026 via restricted stock vesting as compensation. The planned sale is expected around 02/09/2026 on the NASDAQ. Over the prior three months, Metzger sold 7,412 common shares for gross proceeds of $152,836.18, also reported in the filing.
Syndax Pharmaceuticals shareholder files notice to sell shares. A person named Keith A. Goldan filed a Form 144 covering the planned sale of 3,410 shares of common stock through Fidelity Brokerage Services LLC on the NASDAQ, with an aggregate market value of 71,706.84 and 86,914,838 shares outstanding.
The shares to be sold were acquired as restricted stock vesting on 02/06/2026 from the issuer as compensation. The form also reports that during the past three months, this person sold 2,082 common shares on 02/06/2026 for gross proceeds of 42,931.05. The filer represents that they are not aware of undisclosed material adverse information about the company.
STATE STREET CORPORATION reported a significant ownership stake in Syndax Pharmaceuticals Inc. common stock. As of 12/31/2025, it beneficially owned 4,596,552 shares, representing 5.3% of the company’s common stock.
State Street reported no sole voting or dispositive power, but shared voting power over 4,341,322 shares and shared dispositive power over 4,596,552 shares. The position is certified as being held in the ordinary course of business and not for influencing control of Syndax.